Targeted Oncologic Therapies Demand New Approach to Phase II/III Trials

Targeted cancer therapies should be studied in large Phase II programs that incorporate biomarkers, a panelist said at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla